These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 38722401)

  • 1. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
    J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
    Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
    Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma.
    Wu D; Liu Y; Liu J; Ma L; Tong X
    Sci Rep; 2024 Jul; 14(1):17460. PubMed ID: 39075165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the immune landscape and drug prediction of an M2 tumor-associated macrophage-related gene signature in EGFR-negative lung adenocarcinoma.
    Huang Y; Zhang Y; Duan X; Hou R; Wang Q; Shi J
    Thorac Cancer; 2024 Jul; 15(21):1626-1637. PubMed ID: 38886907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the molecular and immune landscape of cellular senescence in lung adenocarcinoma.
    Ru K; Cui L; Wu C; Tan XX; An WT; Wu Q; Ma YT; Hao Y; Xiao X; Bai J; Liu X; Xia XF; Zhao MQ
    Front Immunol; 2024; 15():1347770. PubMed ID: 39267750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus clustering and novel risk score model construction based on m6A methylation regulators to evaluate the prognosis and tumor immune microenvironment of early-stage lung adenocarcinoma.
    He M; Zhi Y; Li C; Zhao C; Yang G; Lv J; You H; Huang H; Cao X
    Aging (Albany NY); 2024 Jul; 16(14):11318-11338. PubMed ID: 39028290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Cell Death Index for Lung Adenocarcinoma: A Comprehensive Transcriptome-Based Analysis of Twelve Programmed Cell Death Pattern Genes.
    Chen F; Ma J; Hu S; Wu C; Chen S; Lin J
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):135. PubMed ID: 38682187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
    Front Immunol; 2021; 12():677169. PubMed ID: 34354701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.
    Yang J; Liu K; Yang L; Ji J; Qin J; Deng H; Wang Z
    Front Immunol; 2023; 14():1174762. PubMed ID: 37287976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in lung adenocarcinoma.
    Xiaona X; Liu Q; Zhou X; Liang R; Yang S; Xu M; Zhao H; Li C; Chen Y; Xueding C
    Comput Biol Med; 2023 May; 158():106831. PubMed ID: 37037146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 20. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
    Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
    Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.